Skip to main content
    C

    Cingulate Inc (CING)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.39
    -0.18 (-3.94%)

    Market Cap: $68.64M

    Last updated: Oct 16, 2026 at 1:54 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    42%(8/19)
    Avg Surprise
    -12.22%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.45
    Range$-0.55 - $-0.39
    3 analysts
    EPS Revisions
    2
    0
    7d
    2
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.67+33.0%
    60d ago$-0.53+15.2%
    30d ago$-0.53+15.2%
    7d ago$-0.53+15.2%
    Current$-0.45
    Revenue Consensus
    $0
    Range$0 - $0
    4 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.65
    Range$-0.84 - $-0.50
    4 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    4 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.65---
    Sep 26EST
    		-$-0.45---
    Jun 26
    Reported Aug 13
    		$-0.45$-0.63+28.57%Beat+58.7%
    Mar 26
    Reported May 14
    		$-0.95$-0.53-79.25%Miss+8.7%
    Dec 25
    Reported Mar 18
    		$-0.84$-1.55+45.81%Beat+77.2%
    Sep 25
    Reported Nov 13
    		$-1.35$-0.75-80.00%Miss+26.2%
    Jun 25
    Reported Aug 19
    		$-1.09$-0.82-32.93%Miss+80.1%
    Mar 25
    Reported May 8
    		$-1.04$-0.98-6.12%Miss+94.6%
    Dec 24
    Reported Mar 27
    		$-3.68$-2.93-25.60%Miss+52.0%
    Sep 24
    Reported Nov 7
    		$-1.83$-2.22+17.57%Beat+97.5%
    Jun 24
    Reported Aug 13
    		$-5.47$-4.92-11.18%Miss+96.0%
    Mar 24
    Reported May 8
    		$-19.20N/A+63.58%Beat+77.1%
    Dec 23
    Reported Mar 29
    		$-7.66$-4.86-57.61%Miss-1768.3%
    Sep 23
    Reported Nov 13
    		$-72.00$-90.40+20.35%Beat+16.7%
    Jun 23
    Reported Aug 14
    		$-136.80$-81.60-67.65%Miss-58.3%
    Mar 23
    Reported May 10
    		$-84.00$-77.60-8.25%Miss+20.5%
    Dec 22
    Reported Mar 10
    		$-0.41$-0.37-10.81%Miss-28.1%
    Sep 22
    Reported Nov 14
    		$-86.40$-88.80+2.70%Beat-6160.9%
    Jun 22
    Reported Aug 11
    		$-86.40$-139.20+37.93%Beat-24585.7%
    Mar 22
    Reported May 12
    		$-105.60$-56.40-87.23%Miss-
    Dec 21
    Reported Mar 10
    		$-0.32$-0.39+17.95%Beat-
    Sep 21
    Reported Dec 9
    		$-1.38$0.00N/AMiss-
    Jun 21
    Reported Sep 27
    		$-0.35$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-1.22EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-198.70%ROICN/A
    Financial Health
    Debt/Equity0.22xInterest CoverageN/A
    Current Ratio3.50xQuick Ratio3.50x
    Trading Statistics
    Beta-0.88Avg Volume93.27K
    52-Week High$11.8952-Week Low$3.16

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$4.76
    SMA 20$4.87
    SMA 50$5.09
    SMA 200$5.43
    EMA 10$4.72
    EMA 20$4.84
    EMA 50$4.96
    EMA 200$5.04

    MACD

    Line: -0.13Signal: -0.09Hist: -0.04

    ADX

    ADX: 24.1+DI: 9.3-DI: 30.5

    Aroon & PSAR

    Aroon Up28.0
    Aroon Down100.0
    PSAR$4.96

    Bollinger Bands

    Upper Band$5.28
    Lower Band$4.47
    %B Position1671%(Upper)
    Band Width-0.09

    RSI (14-Day)

    Oversold
    28.7

    Momentum Oscillators

    Stoch %K13.6
    Stoch %D23.3
    Williams %R-85.1
    ROC (10d)-7.6%
    Momentum-0.36
    CCI (20d)-229.4
    MFI (14d)28.4

    Volatility Measures

    ATR (14d)$0.24(5.5%)
    StdDev (20d)0.20
    Hist Vol34.4%(Moderate)

    Volume Flow

    VWAP$4.42
    OBV-3.1M
    AD Line-7.0M
    CMF (20d)-0.192

    Volume Metrics

    Avg Vol (20d)92.5K
    Vol Ratio1.9x(High)
    VWMA (20d)$4.84

    Pivot Points

    R3$4.91
    R2$4.84
    R1$4.71
    Pivot Point$4.63
    S1$4.50
    S2$4.43
    S3$4.29

    Advanced Oscillators

    TSI-21.48
    Ultimate Osc41.7
    KST-80.86

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$12.98B$0$0$0N/A$0
    Cost of Revenue$0$0$-419,062$0$0$0$160,302$0$0$0N/A$0
    Gross Profit$0$0$419,062$0$0$0$-160,302$0$0$0N/A$0
    Operating Expenses$5.41M$7.92M$5.59M$6.00M$4.65M$3.71M$6.21M$3.28M$3.21M$2.95M$6.80M$5.75M
    R&D$1.49M$2.18M$2.00M$2.85M$2.70M$2.22M$4.33M$1.43M$1.88M$1.81M$4.98M$3.92M
    SG&A$3.93M$5.74M$3.58M$3.15M$1.95M$1.48M$1.88M$1.85M$1.33M$1.14M$1.81M$1.83M
    Operating Income$-5,414,975$-7,923,222$-5,586,264$-5,995,835$-4,649,974$-3,706,035$-6,208,489$-3,282,087$-3,206,180$-2,948,217$-6,797,151$-5,749,674
    Interest Income$-141,276$-536,837$0$0$-138,761$-96,656$0$0$0$0$0$0
    Interest Expense$455,289$1.39M$1.36M$1.35M$333,287$146,643$0$843,556$3,497$24,260$137,546$229,380
    Income Before Tax$-5,870,264$-9,312,089$-6,272,910$-7,341,062$-4,983,261$-3,852,678$-6,131,979$-4,125,643$-3,209,677$-2,972,477$-6,934,697$-5,979,054
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-5,870,264$-9,312,089$-6,272,910$-7,341,062$-4,983,261$-3,852,678$-6,131,979$-4,125,643$-3,209,677$-2,972,477$-6,934,697$-5,979,054
    EBITDA$-5,630,745$-8,648,505$-5,464,116$-7,367,584$-4,619,352$-3,513,755$-6,048,187$-3,960,236$-3,042,399$-2,784,617$-6,624,826$-5,595,011
    EBIT$-5,728,988$-8,775,252$-5,585,948$-7,341,062$-4,844,500$-3,756,022$-6,208,489$-4,125,643$-3,206,180$-2,948,217$-6,797,151$-5,749,674
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about CING

    News

    Cingulate Extends Trial Period for Chief Medical Officer

    Cingulate Inc. has extended the trial period for its Chief Medical Officer, Matthew N. Brams, until December 31, 2026...

    The Globe and Mail•10/3/26•Neutral

    Shane Schaffer, Cingulate Chairman & CEO to Present "SMART Launch” Approach at Indegene Digital Summit: Rethinking Commercialization for Emerging Pharma

    Cingulate Inc.'s Chairman and CEO, Shane J. Schaffer, and Chief Commercial Officer, Bryan Downey, will present at the Indegene Digital Summit. They will discuss Cingulate's "SMART Launch" approach...

    The Manila Times•9/17/26•Somewhat-Bullish

    Shane Schaffer, Cingulate Chairman & CEO to Present “SMART Launch” Approach at Indegene Digital Summit: Rethinking Commercialization for Emerging Pharma

    Cingulate Inc. Chairman and CEO Shane J. Schaffer and Chief Commercial Officer Bryan Downey will present at the Indegene Digital Summit on September 22, 2026...

    GlobeNewswire•9/17/26•Somewhat-Bullish

    CINGULATE INC : ASCENDIANT CAPITAL MARKETS CUTS TARGET PRICE TO $44 FROM $52

    Ascendiant Capital Markets has reduced its target price for CINGULATE INC (CING.O) to $44 from $52. This update reflects a change in the analyst's outlook for the company. The article, sourced from Reuters...

    Bitget•8/20/26•Bearish

    Ascendiant Capital Markets Cuts Cingulate (NASDAQ:CING) Price Target to $44.00

    Ascendiant Capital Markets has reduced its price target for Cingulate (NASDAQ:CING) from $52.00 to $44.00, while maintaining a "buy" rating. Despite the lowered target...

    MarketBeat•8/20/26•Somewhat-Bearish

    CING Valuation and Fair Value

    P/E
    -1.2x
    P/B
    2.5x
    See GNG's fair value

    CING Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -198.7%

    CING Competitors

    CompanyTicker
    Heron TherapeutiHRTX
    Microbot Medical IncMBOT
    Fortress Biotech IncFBIO
    Spero Therapeutics IncSPRO
    Coeptis Therapeutics IncCOEP
    Champions Oncology IncCSBR
    Oncolytics Biotech IncONCY
    Neumora Therapeutics, Inc.NMRA

    Sector: Healthcare

    CING Analyst Ratings

    Consensus
    Buy
    Analysts
    4
    Strong Buy
    1
    Buy
    3
    Hold
    0
    Sell
    0
    Strong Sell
    0

    CING Bull Case vs Bear Case

    Bear case

    • CING beat EPS estimates in 37.5% of its last 8 reported quarters.

    CING Earnings: Beat Rate and Next Report

    Beat rate
    3 of 8 quarters (37.5%)
    Average surprise
    -16.5%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.45
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    2 up, 1 down

    Frequently Asked Questions About CING

    Does CING pay dividends?

    Cingulate Inc (CING) does not currently pay a regular dividend.

    What is CING's market cap?

    Cingulate Inc (CING) has a market capitalization of $68.64M with a current stock price of $4.39.

    Related stocks

    Sector: Healthcare

    All stocks starting with C

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In